Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Cytori Therapeutic’s common stock to begin trading on adjusted basis on May 24, following one-for-ten reverse split

GlobeNewswire May 23, 2018

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.

Business Wire May 18, 2018

Cytori Reports Q1 2018 Business and Financial Results

GlobeNewswire May 10, 2018

Cytori to Webcast First Quarter Financial Results on May 10

GlobeNewswire May 7, 2018

Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin

GlobeNewswire April 30, 2018

Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence

GlobeNewswire March 28, 2018

Cytori Announces Corporate Restructuring & Cost Reduction Plan

GlobeNewswire September 1, 2017

Investor Network: Cytori Therapeutics, Inc. to Host Earnings Call

Accesswire August 10, 2017

Cytori to Webcast Second Quarter Financial Results on August 10

GlobeNewswire August 4, 2017

Cytori Therapeutics Announces Inducement Grants for New Employees

GlobeNewswire July 25, 2017

20 Biggest Mid-Day Losers For Tuesday

Benzinga.com  July 25, 2017

The Market In 5 Minutes

Benzinga.com  July 25, 2017

Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma

GlobeNewswire July 24, 2017

American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy

GlobeNewswire July 10, 2017

Cytori Receives Key Cell Therapy Patent for Scleroderma

GlobeNewswire July 6, 2017

Today's Research Report Coverage on Biotech Stocks -- Cyclacel Pharma, Cytori Therapeutics, La Jolla Pharma, and Moleculin Biotech

PR Newswire June 19, 2017

Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America

GlobeNewswire June 14, 2017

Long Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy

GlobeNewswire June 8, 2017

Cytori to Introduce Next-Generation Celution® Technology

GlobeNewswire June 1, 2017

Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial

GlobeNewswire May 31, 2017